Shopping Cart
- Remove All
- Your shopping cart is currently empty
Lenzilumab (KB 003) is a humanized granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibody that directly binds to GM-CSF and prevents signaling through its receptor, and can be used to study COVID-19.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $385 | In Stock | |
5 mg | $1,150 | In Stock | |
10 mg | $1,730 | In Stock | |
25 mg | $2,940 | In Stock |
Description | Lenzilumab (KB 003) is a humanized granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibody that directly binds to GM-CSF and prevents signaling through its receptor, and can be used to study COVID-19. |
In vivo | Intraperitoneal injection of 10 mg/kg Lenzilumab once daily for 10 days improved its antitumor effect in NSG mice by inhibiting GM-CSF without impairing the cellular function of CAR-T and at the same time. [1] |
Alias | KB003, KB 003 |
Cas No. | 1229575-09-0 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.